Twitter (TWTR) tanks as Q2 user growth vanishes >>> READ MORE

5 Biotechnology Stocks to Sell Now

SVA, CRIS, PGNX, IRWD, EXEL slump in weekly rankings


This week, the ratings of five Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Sinovac Biotech‘s (NASDAQ:SVA) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Sinovac Biotech researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity, and Cash Flow, SVA also gets an F. While the Nasdaq has remained flat over the past month, the stock price has fallen 7% over the past month. For more information, get Portfolio Grader’s complete analysis of SVA stock.

Curis Inc.‘s (NASDAQ:CRIS) rating weakens this week, dropping to a D versus last week’s C. Curis is a drug discovery and development company that engages in the research and development of cancer therapeutics. Investors seem to agree with the downgrade and have pushed down the share price 12.4% over the past month. The stock currently has a trailing PE Ratio of 105.70. For a full analysis of CRIS stock, visit Portfolio Grader.

Slipping from a C to a D rating, Progenics Pharmaceuticals (NASDAQ:PGNX) takes a hit this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. In Earnings Momentum, Earnings Revisions, Equity, and Sales Growth the stock gets F’s. Wall Street appears to agree with the stock downgrade, with share prices dropping 22.7% over the past month. To get an in-depth look at PGNX, get Portfolio Grader’s complete analysis of PGNX stock.

Ironwood Pharmaceuticals (NASDAQ:IRWD) earns a D this week, falling from last week’s grade of C. Ironwood Pharmaceuticals discovers, develops, manufactures, and commercializes marketed drugs. The stock also gets an F in Equity. The stock price has fallen 5.9% over the past month. For a full analysis of IRWD stock, visit Portfolio Grader.

This week, Exelixis (NASDAQ:EXEL) drops from a C to a D rating. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. Share prices fell 6.6% over the past month. As of Dec. 5, 2012, 22% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC